Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma

The foundation of precision immunotherapy in oncology is rooted in computational biology and patient-derived sample sequencing to enrich for and target immunogenic epitopes. Discovery of these tumor-specific epitopes through tumor sequencing has revolutionized patient outcomes in many types of cance...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of molecular sciences 2021-03, Vol.22 (7), p.3455
Hauptverfasser: Lookian, Pashayar P, Zhao, David, Medina, Rogelio, Wang, Herui, Zenka, Jan, Gilbert, Mark R, Pacak, Karel, Zhuang, Zhengping
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 7
container_start_page 3455
container_title International journal of molecular sciences
container_volume 22
creator Lookian, Pashayar P
Zhao, David
Medina, Rogelio
Wang, Herui
Zenka, Jan
Gilbert, Mark R
Pacak, Karel
Zhuang, Zhengping
description The foundation of precision immunotherapy in oncology is rooted in computational biology and patient-derived sample sequencing to enrich for and target immunogenic epitopes. Discovery of these tumor-specific epitopes through tumor sequencing has revolutionized patient outcomes in many types of cancers that were previously untreatable. However, these therapeutic successes are far from universal, especially with cancers that carry high intratumoral heterogeneity such as glioblastoma (GBM). Herein, we present the technical aspects of Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) vaccine immunotherapy, an investigational therapeutic that potentially circumvents the need for in silico tumor-neoantigen enrichment. We then review the most promising GBM vaccination strategies to contextualize the MBTA vaccine. By reviewing current evidence using translational tumor models supporting MBTA vaccination, we evaluate the underlying principles that validate its clinical applicability. Finally, we showcase the translational potential of MBTA vaccination as a potential immunotherapy in GBM, along with established surgical and immunologic cancer treatment paradigms.
doi_str_mv 10.3390/ijms22073455
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8037428</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2548796566</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-998a9f6fa55be273d27d5be91112338f657d90326c2449ce85272a2a03461ccd3</originalsourceid><addsrcrecordid>eNpdkV1rFDEYhYMo9kPvvJaANxV2ar4z44Uw3da2sItQVm9DNpNps8wkYzKzZX-Bf9vU1rJ69R54Hw7ncAB4h9EppRX65DZ9IgRJyjh_AQ4xI6RASMiXe_oAHKW0QYhQwqvX4IDSEiOB5SH4tdTea1-c1csZXC1u4MLdat-kGaz96Ir5OUN_1Do0O3iyPFvVH-EPbYzzFl73_eTDeGejHnafYQ1v7NbZexhaOJ9itH6EF1vXWG8szJ6wHobOGT264BN0Hl52Lqw7ncbQ6zfgVau7ZN8-3WPw_evFan5VLL5dXs_rRWEYJmNRVaWuWtFqzteWSNoQ2WRVYYxJLtUKLpsKUSIMYawytuREEk00okxgYxp6DL48-g7TureNySGj7tQQXa_jTgXt1L8f7-7UbdiqElHJSJkNTp4MYvg52TSq3iVju057G6akCEclF0wImdEP_6GbMEWf62WKlbISXIhMzR4pE0NK0bbPYTBSDwur_YUz_n6_wDP8d1L6G08voAk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2548796566</pqid></control><display><type>article</type><title>Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Lookian, Pashayar P ; Zhao, David ; Medina, Rogelio ; Wang, Herui ; Zenka, Jan ; Gilbert, Mark R ; Pacak, Karel ; Zhuang, Zhengping</creator><creatorcontrib>Lookian, Pashayar P ; Zhao, David ; Medina, Rogelio ; Wang, Herui ; Zenka, Jan ; Gilbert, Mark R ; Pacak, Karel ; Zhuang, Zhengping</creatorcontrib><description>The foundation of precision immunotherapy in oncology is rooted in computational biology and patient-derived sample sequencing to enrich for and target immunogenic epitopes. Discovery of these tumor-specific epitopes through tumor sequencing has revolutionized patient outcomes in many types of cancers that were previously untreatable. However, these therapeutic successes are far from universal, especially with cancers that carry high intratumoral heterogeneity such as glioblastoma (GBM). Herein, we present the technical aspects of Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) vaccine immunotherapy, an investigational therapeutic that potentially circumvents the need for in silico tumor-neoantigen enrichment. We then review the most promising GBM vaccination strategies to contextualize the MBTA vaccine. By reviewing current evidence using translational tumor models supporting MBTA vaccination, we evaluate the underlying principles that validate its clinical applicability. Finally, we showcase the translational potential of MBTA vaccination as a potential immunotherapy in GBM, along with established surgical and immunologic cancer treatment paradigms.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms22073455</identifier><identifier>PMID: 33810617</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antigens ; Brain cancer ; CD40 antigen ; Cell cycle ; Clinical trials ; Computer applications ; Dendritic cells ; Drug therapy ; Epitopes ; Glioblastoma ; Heterogeneity ; Immune system ; Immunogenicity ; Immunotherapy ; Ligands ; Mannan ; Medical prognosis ; Monoclonal antibodies ; Mutation ; Neoantigens ; Nervous system ; Patients ; Peptides ; Proteins ; Radiation ; Review ; Translation ; Tumors ; Vaccination ; Vaccines</subject><ispartof>International journal of molecular sciences, 2021-03, Vol.22 (7), p.3455</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-998a9f6fa55be273d27d5be91112338f657d90326c2449ce85272a2a03461ccd3</citedby><cites>FETCH-LOGICAL-c412t-998a9f6fa55be273d27d5be91112338f657d90326c2449ce85272a2a03461ccd3</cites><orcidid>0000-0003-2293-4819 ; 0000-0003-0260-5268</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037428/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037428/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33810617$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lookian, Pashayar P</creatorcontrib><creatorcontrib>Zhao, David</creatorcontrib><creatorcontrib>Medina, Rogelio</creatorcontrib><creatorcontrib>Wang, Herui</creatorcontrib><creatorcontrib>Zenka, Jan</creatorcontrib><creatorcontrib>Gilbert, Mark R</creatorcontrib><creatorcontrib>Pacak, Karel</creatorcontrib><creatorcontrib>Zhuang, Zhengping</creatorcontrib><title>Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>The foundation of precision immunotherapy in oncology is rooted in computational biology and patient-derived sample sequencing to enrich for and target immunogenic epitopes. Discovery of these tumor-specific epitopes through tumor sequencing has revolutionized patient outcomes in many types of cancers that were previously untreatable. However, these therapeutic successes are far from universal, especially with cancers that carry high intratumoral heterogeneity such as glioblastoma (GBM). Herein, we present the technical aspects of Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) vaccine immunotherapy, an investigational therapeutic that potentially circumvents the need for in silico tumor-neoantigen enrichment. We then review the most promising GBM vaccination strategies to contextualize the MBTA vaccine. By reviewing current evidence using translational tumor models supporting MBTA vaccination, we evaluate the underlying principles that validate its clinical applicability. Finally, we showcase the translational potential of MBTA vaccination as a potential immunotherapy in GBM, along with established surgical and immunologic cancer treatment paradigms.</description><subject>Antigens</subject><subject>Brain cancer</subject><subject>CD40 antigen</subject><subject>Cell cycle</subject><subject>Clinical trials</subject><subject>Computer applications</subject><subject>Dendritic cells</subject><subject>Drug therapy</subject><subject>Epitopes</subject><subject>Glioblastoma</subject><subject>Heterogeneity</subject><subject>Immune system</subject><subject>Immunogenicity</subject><subject>Immunotherapy</subject><subject>Ligands</subject><subject>Mannan</subject><subject>Medical prognosis</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>Neoantigens</subject><subject>Nervous system</subject><subject>Patients</subject><subject>Peptides</subject><subject>Proteins</subject><subject>Radiation</subject><subject>Review</subject><subject>Translation</subject><subject>Tumors</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkV1rFDEYhYMo9kPvvJaANxV2ar4z44Uw3da2sItQVm9DNpNps8wkYzKzZX-Bf9vU1rJ69R54Hw7ncAB4h9EppRX65DZ9IgRJyjh_AQ4xI6RASMiXe_oAHKW0QYhQwqvX4IDSEiOB5SH4tdTea1-c1csZXC1u4MLdat-kGaz96Ir5OUN_1Do0O3iyPFvVH-EPbYzzFl73_eTDeGejHnafYQ1v7NbZexhaOJ9itH6EF1vXWG8szJ6wHobOGT264BN0Hl52Lqw7ncbQ6zfgVau7ZN8-3WPw_evFan5VLL5dXs_rRWEYJmNRVaWuWtFqzteWSNoQ2WRVYYxJLtUKLpsKUSIMYawytuREEk00okxgYxp6DL48-g7TureNySGj7tQQXa_jTgXt1L8f7-7UbdiqElHJSJkNTp4MYvg52TSq3iVju057G6akCEclF0wImdEP_6GbMEWf62WKlbISXIhMzR4pE0NK0bbPYTBSDwur_YUz_n6_wDP8d1L6G08voAk</recordid><startdate>20210326</startdate><enddate>20210326</enddate><creator>Lookian, Pashayar P</creator><creator>Zhao, David</creator><creator>Medina, Rogelio</creator><creator>Wang, Herui</creator><creator>Zenka, Jan</creator><creator>Gilbert, Mark R</creator><creator>Pacak, Karel</creator><creator>Zhuang, Zhengping</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2293-4819</orcidid><orcidid>https://orcid.org/0000-0003-0260-5268</orcidid></search><sort><creationdate>20210326</creationdate><title>Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma</title><author>Lookian, Pashayar P ; Zhao, David ; Medina, Rogelio ; Wang, Herui ; Zenka, Jan ; Gilbert, Mark R ; Pacak, Karel ; Zhuang, Zhengping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-998a9f6fa55be273d27d5be91112338f657d90326c2449ce85272a2a03461ccd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>Brain cancer</topic><topic>CD40 antigen</topic><topic>Cell cycle</topic><topic>Clinical trials</topic><topic>Computer applications</topic><topic>Dendritic cells</topic><topic>Drug therapy</topic><topic>Epitopes</topic><topic>Glioblastoma</topic><topic>Heterogeneity</topic><topic>Immune system</topic><topic>Immunogenicity</topic><topic>Immunotherapy</topic><topic>Ligands</topic><topic>Mannan</topic><topic>Medical prognosis</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>Neoantigens</topic><topic>Nervous system</topic><topic>Patients</topic><topic>Peptides</topic><topic>Proteins</topic><topic>Radiation</topic><topic>Review</topic><topic>Translation</topic><topic>Tumors</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lookian, Pashayar P</creatorcontrib><creatorcontrib>Zhao, David</creatorcontrib><creatorcontrib>Medina, Rogelio</creatorcontrib><creatorcontrib>Wang, Herui</creatorcontrib><creatorcontrib>Zenka, Jan</creatorcontrib><creatorcontrib>Gilbert, Mark R</creatorcontrib><creatorcontrib>Pacak, Karel</creatorcontrib><creatorcontrib>Zhuang, Zhengping</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lookian, Pashayar P</au><au>Zhao, David</au><au>Medina, Rogelio</au><au>Wang, Herui</au><au>Zenka, Jan</au><au>Gilbert, Mark R</au><au>Pacak, Karel</au><au>Zhuang, Zhengping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2021-03-26</date><risdate>2021</risdate><volume>22</volume><issue>7</issue><spage>3455</spage><pages>3455-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>The foundation of precision immunotherapy in oncology is rooted in computational biology and patient-derived sample sequencing to enrich for and target immunogenic epitopes. Discovery of these tumor-specific epitopes through tumor sequencing has revolutionized patient outcomes in many types of cancers that were previously untreatable. However, these therapeutic successes are far from universal, especially with cancers that carry high intratumoral heterogeneity such as glioblastoma (GBM). Herein, we present the technical aspects of Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) vaccine immunotherapy, an investigational therapeutic that potentially circumvents the need for in silico tumor-neoantigen enrichment. We then review the most promising GBM vaccination strategies to contextualize the MBTA vaccine. By reviewing current evidence using translational tumor models supporting MBTA vaccination, we evaluate the underlying principles that validate its clinical applicability. Finally, we showcase the translational potential of MBTA vaccination as a potential immunotherapy in GBM, along with established surgical and immunologic cancer treatment paradigms.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>33810617</pmid><doi>10.3390/ijms22073455</doi><orcidid>https://orcid.org/0000-0003-2293-4819</orcidid><orcidid>https://orcid.org/0000-0003-0260-5268</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2021-03, Vol.22 (7), p.3455
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8037428
source MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Antigens
Brain cancer
CD40 antigen
Cell cycle
Clinical trials
Computer applications
Dendritic cells
Drug therapy
Epitopes
Glioblastoma
Heterogeneity
Immune system
Immunogenicity
Immunotherapy
Ligands
Mannan
Medical prognosis
Monoclonal antibodies
Mutation
Neoantigens
Nervous system
Patients
Peptides
Proteins
Radiation
Review
Translation
Tumors
Vaccination
Vaccines
title Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T22%3A24%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mannan-BAM,%20TLR%20Ligands,%20Anti-CD40%20Antibody%20(MBTA)%20Vaccine%20Immunotherapy:%20A%20Review%20of%20Current%20Evidence%20and%20Applications%20in%20Glioblastoma&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Lookian,%20Pashayar%20P&rft.date=2021-03-26&rft.volume=22&rft.issue=7&rft.spage=3455&rft.pages=3455-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms22073455&rft_dat=%3Cproquest_pubme%3E2548796566%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2548796566&rft_id=info:pmid/33810617&rfr_iscdi=true